TB-500 Dosage in the Research Literature | MD/TB-500
TB-500 Dosage in the Research Literature
TB-500 dosage data in the published literature varies substantially by species, model, route, and whether the study used the 7-residue heptapeptide fragment or the full-length 43-amino-acid thymosin beta-4 parent protein. The following records what has been studied in the literature — not what has been approved, prescribed, or recommended for humans. No TB-500 dosage has been validated in any human clinical trial.
The three evidence strata:
Rodent (in vivo). Wound-healing and tissue-repair models in rats and mice have used 0.5-5 mg/kg body weight by intraperitoneal or subcutaneous route. Diabetic burn wound models used intradermal injection twice weekly at an unspecified dose [10]. Post-molar-extraction rat studies used intraperitoneal injection at unspecified doses [11]. These are research doses administered to animals under controlled laboratory conditions.
Equine. Commercial lyophilized TB-500 preparations for equine use have been documented at 2-5 mg per vial. The anti-doping literature describes single-dose administration to horses for LC-MS/MS detection validation [8]. No published equine clinical trial has established a therapeutic dosing protocol for the heptapeptide in horses.
Human (full-length thymosin beta-4 parent, not TB-500 fragment). A Phase 1 IV safety study in healthy volunteers used four ascending dose cohorts of 42, 140, 420, and 1260 mg as single doses, followed by 14-day daily dosing at the same levels [9]. A first-in-human Phase 1 of recombinant thymosin beta-4 in 84 Chinese volunteers used single doses of 0.05-25.0 ug/kg with a multiple-dose arm at three levels for 10 days [12]. Both studies confirmed dose-proportional pharmacokinetics and no dose-limiting toxicity for the full-length parent protein. These doses are not applicable to TB-500.
TB-500 Half-Life and Pharmacokinetics
How long does TB-500 stay in your system? Plasma half-life data for the TB-500 heptapeptide fragment (Ac-LKKTETQ) are not established in published peer-reviewed literature. No human pharmacokinetic study of the heptapeptide has been published as of 2026.
For the full-length thymosin beta-4 parent protein, the Phase 1 IV human study showed dose-proportional pharmacokinetics and an increasing half-life with increasing dose [9]. The recombinant human Phase 1 study found no drug accumulation on repeat dosing [12], consistent with clearance between doses.
Preclinical data suggest plasma clearance of the intact heptapeptide is relatively rapid — sub-hour to a few hours — based on general peptide pharmacokinetic principles. Tissue-level bioactivity, however, may persist beyond plasma clearance given the ILK/PINCH complex formation and NF-kB pathway effects documented in cell studies.
The equine doping literature confirms TB-500 and its metabolites are detectable in equine plasma (limit of detection 0.02 ng/mL) and urine (0.01 ng/mL) by WADA-accredited LC-MS/MS [8]. Detection windows in equine specimens post-administration have been characterized; human detection windows have not been validated in published literature.
TB-500 Injection Site: Local vs. Systemic
Does TB-500 need to be injected near the injury? Animal studies indicate systemic distribution regardless of injection site. Subcutaneous administration at distal sites in rodent models still reaches target tissues, suggesting localized injection is not required for bioavailability based on the preclinical data.
Thymosin beta-4 is described as a multifunctional tissue repair and regeneration peptide showing systemic as well as local effects in multiple animal models [1]. The anti-inflammatory NF-kB inhibition mechanism documented in corneal epithelial cells [14] operated in the context of topical ophthalmic application, demonstrating that local routes are effective for local tissue targets. Whether subcutaneous injection distant from an injury reaches the injured tissue at pharmacologically relevant concentrations in humans has not been validated in any published human study.
Routes studied across the research literature include: subcutaneous (rodent and equine models), intraperitoneal (rodent models), topical/local application (wound and corneal models), and intravenous (human Phase 1 studies of full-length thymosin beta-4).
TB-500 Onset of Effect in Research Studies
How long does TB-500 take to work? In rodent wound-healing models, measurable tissue-repair markers appear within 48-72 hours of first administration. The 2024 rat skin wound study showed measurable enhanced angiogenesis at day 3, with new epithelial thickness increasing throughout the healing timeline [13]. The 2014 diabetic burn wound mouse model documented improved wound closure and granulation over repeated twice-weekly dosing [10].
Equine regulatory literature describes loading phases of 4-6 weeks followed by maintenance dosing. This pattern reflects clinical observations in the equine veterinary context, not a validated human protocol. Human clinical rationale for cycle length has not been established in peer-reviewed literature for TB-500 specifically.
The onset data from rodent models cannot be directly extrapolated to human tissue repair given differences in wound-healing kinetics, metabolic rate, and body mass.
TB-500 Cycle Length in Study Protocols
How long should a standard TB-500 cycle last? The equine anti-doping and veterinary literature describes loading phases of 4-6 weeks, sometimes followed by maintenance administration. These protocols are referenced in the context of equestrian sport compliance, not clinical therapy.
No published randomized controlled trial has established a cycle duration for TB-500 in humans. The Phase 1 human safety studies of full-length thymosin beta-4 used multi-dose arms of 14 days [9] and 10 days [12] — these are pharmacokinetic observation windows, not therapeutic cycle recommendations.
The rodent wound studies used protocols calibrated to wound healing timelines in the specific animal model, which do not translate directly to human tissue repair timescales.
TB-500 Reconstitution in Research Settings
What is the standard reconstitution protocol for TB-500? Laboratory reconstitution of lyophilized TB-500 typically uses bacteriostatic water (0.9% benzyl alcohol as a preservative). Standard lyophilized vial concentrations in published equine studies and research laboratory contexts range from 2-5 mg per vial.
Storage conditions documented in the equine and laboratory literature: lyophilized (pre-reconstitution) storage at -20°C; reconstituted solution storage at 2-8°C. These are standard laboratory conditions for peptide research reagents.
Bacteriostatic water or sterile water for injection are both referenced as reconstitution vehicles in laboratory contexts. The benzyl alcohol preservative in bacteriostatic water extends the usable life of a reconstituted solution under refrigeration.
These reconstitution details reflect practices in equine and laboratory research settings, not approved pharmaceutical preparation protocols for humans.